Framingham, MA, September 8, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer, will present at the 22nd Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel on Thursday, September 10, 2015 at 10:30 a.m. Eastern Time in New York, NY.
About Alzheon
About Alzheon Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ‐801, is a first in‐class, oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ‐801 is an optimized, novel prodrug that builds on the established safety and efficacy profile of the active compound in clinical trials of more than 2,000 patients. Our mission is to apply our discovery platform and development experience to unlock new classes of therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders.
Media Contact:
Douglas MacDougall
MacDougall Biomedical Communications
781-235-3060
dmacdougall@macbiocom.com